logo

For the Inventor, By the Inventor

Oakland, CA, United States of America

Jonathan A Ellman

This inventor holds 19 USPTO granted patents and 4 published patent applications and 2 EPO patents, primarily in Drug Discovery. Top assignees: University of California, Buck Institute for Research on Aging, Yale University. Active years: 1994-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan A Ellman. Retrieved from https://idiyas.com/inventor/jonathan-a-ellman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19 

% Patents Active = 63.2

 

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 1,018(Granted Patents)


Location History:

  • Berkeley, CA (US) (1994 - 1996)
  • Oakland, CA (US) (2000 - 2013)
  • Guilford, CT (US) (2013 - 2023)

Company Filing History:

goldMedal17 out of 16,048 
 
University of California
 patents
silverMedal2 out of 51 
 
Buck Institute for Research on Aging
 patents
bronzeMedal2 out of 1,370 
 
Yale University
 patents
4. 1 out of 5,644 
 
The University of Texas System
 patents
where one patent can have more than one assignee

Years Active: 1994-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Caspase Inhibitors
Protease Detection
Fibrosis Treatments
Nanoplasmonic Resonator
Bioassay
Small-Molecule Inhibitors
Drug Lead Compounds
Pharmacophore Recombination
Neurodegenerative Disorders
Fluorogenic Materials
Combinatorial Synthesis
Polyol Conversion
19 patents (USPTO):Explore Patents
1. 11773096 - Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same (2023-10-03),
2. 11504373 - Compounds and compositions for treating fibrosis (2022-11-22),
3. 9245290 - Caspase inhibitors and uses thereof (2016-01-26),
4. 9145575 - Detection of protease and protease activity using a single nanocrescent SERS probe (2015-09-29),
5. 8685743 - Real-time, single-step bioassay using nanoplasmonic resonator with ultra-high sensitivity (2014-04-01),
6. 8518942 - Caspase inhibitors and uses thereof (2013-08-27),
7. 8476451 - Tubulysin D analogues (2013-07-02),
8. 8361932 - Detection of protease and protease activity using a single nanoscrescent SERS probe (2013-01-29),
9. 8273926 - Method of converting a polyol to an olefin (2012-09-25),
10. 7629437 - Fluorogenic materials and uses thereof (2009-12-08),
11. 7119105 - Methods for treating neurodegenerative disorders using aspartyl protease inhibitors (2006-10-10),
12. 7001727 - Pharmacophore recombination for the identification of small molecule drug lead compounds (2006-02-21),
13. 6680178 - Profiling of protease specificity using combinatorial fluorogenic substrate libraries (2004-01-20),
14. 6344334 - Pharmacophore recombination for the identification of small molecule drug lead compounds (2002-02-05),
15. 6344330 - Pharmacophore recombination for the identification of small molecule drug lead compounds (2002-02-05),

Title: Jonathan A. Ellman: Innovator in Pharmaceutical Patents

Introduction

Jonathan A. Ellman, based in Oakland, CA, is an accomplished inventor with a remarkable portfolio of 19 patents. His groundbreaking work primarily focuses on small-molecule inhibitors and their therapeutic applications, particularly in the realm of cancer and metabolic disorders.

Latest Patents

Among his latest innovations are novel compounds aimed at treating severe health conditions. One key patent involves small-molecule PI5P4K alpha/beta inhibitors, which disclose the discovery of unique 2-amino-dihydropteridinone compounds capable of inhibiting phosphatidylinositol phosphate kinases. These compounds offer promising avenues for treating p53-null cancer and metabolic disorders such as type 2 diabetes and obesity. Additionally, Ellman holds a patent for compounds and compositions intended for treating fibrosis, offering methods to alleviate diseases modulated by MKP-5.

Career Highlights

Ellman has been associated with reputable institutions, significantly contributing to research and innovation in the pharmaceutical sector. He has worked with the University of California and the Buck Institute for Research on Aging, where his expertise has fostered advancements in health-related technologies.

Collaborations

In his career, Jonathan has collaborated with notable professionals, including Ingrid Choong and Fanqing Frank Chen. These partnerships have further enriched his research endeavors and have been pivotal in the successful development of his patented inventions.

Conclusion

Jonathan A. Ellman's contributions to the field of pharmaceuticals through his patents highlight his commitment to advancing healthcare solutions. His innovative work, particularly in addressing cancer and metabolic disorders, underscores the importance of continued research and development in improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…